Association between change in brain gray matter volume, cognition, and depression severity: Pre- and post- antidepressant pharmacotherapy for late-life depression

Late-life depression (LLD) is associated with cognitive impairments and reduced gray matter volume (GMV); however the mechanisms underlying this association are not well understood. The goal of this study was to characterize changes in depression severity, cognitive function, and brain structure ass...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of psychiatric research Vol. 95; pp. 129 - 134
Main Authors:	Droppa, K., Karim, H.T., Tudorascu, D.L., Karp, J.F., Reynolds, C.F., Aizenstein, H.J., Butters, M.A.
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-12-2017
Subjects:	Aged Antidepressive Agents, Second-Generation - administration & dosage Antidepressive Agents, Second-Generation - pharmacology Cognition Cognitive Dysfunction - drug therapy Cognitive Dysfunction - etiology Cognitive Dysfunction - physiopathology Depressive Disorder, Major - complications Depressive Disorder, Major - drug therapy Depressive Disorder, Major - physiopathology Female Follow-Up Studies Gray Matter - diagnostic imaging Gray Matter - pathology Humans Late-life depression Magnetic Resonance Imaging Male Middle Aged MRI Outcome Assessment (Health Care) Prefrontal Cortex - diagnostic imaging Prefrontal Cortex - pathology Severity of Illness Index Venlafaxine Hydrochloride - administration & dosage Venlafaxine Hydrochloride - pharmacology MRI Late-life depression Cognition
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Late-life depression (LLD) is associated with cognitive impairments and reduced gray matter volume (GMV); however the mechanisms underlying this association are not well understood. The goal of this study was to characterize changes in depression severity, cognitive function, and brain structure associated with pharmacologic antidepressant treatment for LLD. We administered a detailed neurocognitive battery and conducted structural magnetic resonance imaging (MRI) on 26 individuals with LLD, pre-/post-a 12-week treatment trial with venlafaxine. After calculating changes in cognitive performance, GMV, and depression severity, we calculated Pearson's correlations, performed permutation testing, and false discovery rate correction. We found that loss of GMV over 12 weeks in the superior orbital frontal gyrus was associated with less improvement in depression severity and that increased GMV in the same was associated with greater improvement in depression severity. We detected no associations between changes in cognitive performance and improvements in either depressive symptoms or changes in GMV.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0022-3956 1879-1379
DOI:	10.1016/j.jpsychires.2017.08.002